Protalix BioTherapeutics Inc (FRA:PBDA)
€ 1.0305 0.022 (2.18%) Market Cap: 87.92 Mil Enterprise Value: 70.56 Mil PE Ratio: 0 PB Ratio: 3.28 GF Score: 42/100

Q2 2019 Protalix Biotherapeutics Inc Earnings Call Transcript

Aug 08, 2019 / 12:30PM GMT
Release Date Price: €2.93 (-2.33%)
Operator

Good morning, ladies and gentlemen, and welcome to the Protalix Second Quarter 2019 Financial Results and Corporate Conference Call.

(Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to our host, Mr. Lada, investor relations. You may begin your conference.

Alan Lada
SOLEBURY TROUT LLC - VP

Thank you. Hello, everyone, and welcome to Protalix BioTherapeutics' Second Quarter Earnings Results and Corporate Update Conference Call.

With me today is Dror Bashan, Protalix' President and CEO.

A press release announcing the results is available on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experiences to results -- and results to differ materially from the statements made. Factors that could

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot